Repeatability of Positron Emission Tomography (TEP) With fluorométhyl-(18F)-diméthyl-2-hydroxyéthyl-ammonium

NCT ID: NCT03105869

Last Updated: 2017-06-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-16

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Monocentric study. Objective : Determination of the repeatability of fluorocholine PET/CT in prostate cancer

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A second PET/CT with fluorocholine is performed within 2 weeks after a first examination performed in patient referred for an initial prostate cancer or a biological suspicion of relapse.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

test and retest in a single group of patient
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

fluorocholine PET/CT

all patients will undergo a second PET/CT with fluorocholine

Group Type EXPERIMENTAL

fluorocholine PET/CT

Intervention Type DIAGNOSTIC_TEST

standard diagnostic PET/CT procedure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fluorocholine PET/CT

standard diagnostic PET/CT procedure

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* biological suspicion of relapse of prostate cancer or initial staging of prostate cancer
* positive PET/CT with fluororocholine

Exclusion Criteria

-none
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Poitiers University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Catherine CHEZE LE REST

Role: PRINCIPAL_INVESTIGATOR

CHU Poitiers

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RECHOL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
NCT01269593 ACTIVE_NOT_RECRUITING EARLY_PHASE1
[18F]FES PET/.CT in Uterine Cancer
NCT05916196 RECRUITING PHASE2